drugset / Trial / NCT01018095
Trichomonas Vaginalis Recurrence Among HIV+ Women
Phase 4
Completed
270 enrolled
Tulane University Health Sciences Center
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to determine if the 2 gram single dose of metronidazole is as effective as the 7 day 500 mg BID dose for treatment of Trichomonas vaginalis (TV) among HIV-infected women.
Timeline
- Start
- 2005-05
- Primary completion
- 2009-07
- Completion
- 2009-08
Publications
- Kissinger P, Muzny CA, Mena LA, Lillis RA, Schwebke JR, Beauchamps L, Taylor SN, Schmidt N, Myers L, Augostini P, Secor WE, Bradic M, Carlton JM, Martin DH. Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial. Lancet Infect Dis. 2018 Nov;18(11):1251-1259. doi: 10.1016/S1473-3099(18)30423-7. Epub 2018 Oct 5.
- Kissinger P, Mena L, Levison J, Clark RA, Gatski M, Henderson H, Schmidt N, Rosenthal SL, Myers L, Martin DH. A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):565-71. doi: 10.1097/QAI.0b013e3181eda955.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Metronidazole | Small molecule | 500 mg | — |
| Comparator | Metronidazole | Small molecule | 2 g | — |